<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976999</url>
  </required_header>
  <id_info>
    <org_study_id>ICM-BDD2016/04</org_study_id>
    <secondary_id>2016-A01041-50</secondary_id>
    <nct_id>NCT03976999</nct_id>
  </id_info>
  <brief_title>Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers</brief_title>
  <acronym>BCBOvaire</acronym>
  <official_title>Development of a Prospective and Monocentric Cinical and Biological Database in Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primitive Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical and Biological Database will provide to the scientific community a collection of
      blood and tissues with clinical datas to improve knowledge about cancer and help to develope
      new cancer treatments. This database is specific to epithetial ovarian cancer, Fallopian tube
      cancer and Primitive peritoneal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Clinical and Biological Database is a collection of reliable, prospective and
      representative datas.

      This collection, provided to the scientific community, will help to develope research
      programs such as :

        -  Cinicals and biological predictive factors of treatments response

        -  Identification of biological tumoral markers associate with survival

        -  Identification of prognosic factors after recidivism

        -  Diagnostics tests optimisation and follow-up from blood samples ( Circulating Tumor
           Cells (CTC) )

        -  Developing strong preclinical models. Those models would be later used to test
           alternative treatments and would help to identify new biomarkers
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who gave their consent to participate in the study</measure>
    <time_frame>Until the study completion : 3 years</time_frame>
    <description>The proportion of patients who consent to participate in the study among the screened patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Carcinoma, Ovarian Epithelial</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Peritoneal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Biological collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For all the patients include in the studie :
Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)
Tissue samples (tumor tissue and healthy tissue) collected during the surgery
In parallel to this biological collection, standardized clinical data will be entered into a database</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological collection</intervention_name>
    <description>Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)
Tissue samples (tumor tissue and healthy tissue) collected during the surgery</description>
    <arm_group_label>Biological collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 or older

          -  Patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or
             a primitive peritoneal cancer

          -  Patient eligible for, at least, one surgery and a chemotherapy

          -  Patient having given his informed, written and express consent

        Exclusion Criteria:

          -  Patient not affiliated to a social protection scheme

          -  Pregnant and / or nursing women

          -  Subject under tutelage, curatorship or safeguard of justice

          -  Patient whose regular follow-up is impossible for psychological, familial, social or
             geographical reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>COLOMBO Pierre-Emmanuel, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICM - Institut régional du Cancer Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BLEUSE Jean-Pierre, M.D</last_name>
    <phone>+33 4 67 61 31 02</phone>
    <email>DRCI-icm105@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICM - Institut régional du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BLEUSE Jean-Pierre, MD</last_name>
      <phone>0467613102</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-pierre.bleuse@icm.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.</citation>
    <PMID>26742998</PMID>
  </results_reference>
  <results_reference>
    <citation>Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Benítez J, García MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES, Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty SE, Kjær SK, Jensen A, Høgdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine DA, Steele L, Beattie MS, Chan S, Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PD; EMBRACE; kConFab Investigators; Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012 Jan 25;307(4):382-90. doi: 10.1001/jama.2012.20.</citation>
    <PMID>22274685</PMID>
  </results_reference>
  <results_reference>
    <citation>Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 2014 Feb;89(2):207-16. doi: 10.1016/j.critrevonc.2013.08.017. Epub 2013 Sep 8. Review.</citation>
    <PMID>24071502</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011 Oct 12;306(14):1557-65. doi: 10.1001/jama.2011.1456. Erratum in: JAMA. 2012 Jan 25;307(4):363.</citation>
    <PMID>21990299</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biological Specimen Banks</keyword>
  <keyword>Cancer</keyword>
  <keyword>Gynecology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

